|
Diabetes Care, Vol 23, Issue 6 779-785, Copyright © 2000 by American Diabetes Association
Insulin action and insulinemia are closely related to the fasting complement C3, but not acylation stimulating protein concentration
C Weyer, PA Tataranni and RE Pratley
Clinical Diabetes and Nutrition Section, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Phoenix, Arizona 85016, USA. cweyer@phx.niddk.nih.gov
OBJECTIVE: An elevated C3 concentration has been reported in people with
obesity, type 2 diabetes, hypertension, and dyslipidemia, and has been
proposed to play a role in the development of atherosclerosis. We
hypothesized that an elevated C3 concentration might be linked to insulin
resistance and/or hyperinsulinemia, abnormalities commonly observed in
association with the above conditions. RESEARCH DESIGN AND METHODS: Fasting
concentrations of C3 and acylation stimulating protein (ASP, C3adesarg), a
cleavage product of C3 recently found to stimulate glucose uptake in vitro,
were measured in 33 healthy nondiabetic Pima Indians (14 women and 19 men;
age 27 +/- 1 and body fat 33 +/- 1%, means +/- SEM). Subjects were
characterized for body composition dual-energy X-ray absorptiometry,
insulin action (insulin-stimulated glucose disposal [M], hyperinsulinemic
glucose clamp), and glucose tolerance (75-g oral glucose tolerance test).
RESULTS: Fasting C3 and ASP concentrations were positively correlated (r =
0.43, P < 0.05). Fasting C3 concentration was closely related to percent
body fat (r = 0.77), M (r = -0.75), and fasting insulin concentration (r =
0.72) (all P < 0.0001). Fasting C3 concentrations remained significantly
related to M and fasting insulin after adjusting for percent body fat
(partial r = -0.53 and 0.33, both P < 0.05). In subjects with impaired
glucose tolerance, fasting C3 concentrations were higher than in those with
normal glucose tolerance--a difference that remained after adjustment for
percent body fat and M. We found that fasting ASP concentrations were
significantly related to percent body fat (r = 0.37, P < 0.05), but not
to M or fasting insulin. CONCLUSIONS: In Pima Indians, fasting C3
concentration is closely related to adiposity, insulin action, and fasting
insulin levels and may thus be a mediator for the postulated link between
obesity, insulin resistance, hyperinsulinemia, and possibly
atherosclerosis.

CiteULike Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
A. Muscari, S. Antonelli, G. Bianchi, G. Cavrini, S. Dapporto, A. Ligabue, C. Ludovico, D. Magalotti, G. Poggiopollini, M. Zoli, et al.
Serum C3 Is a Stronger Inflammatory Marker of Insulin Resistance Than C-Reactive Protein, Leukocyte Count, and Erythrocyte Sedimentation Rate: Comparison study in an elderly population
Diabetes Care,
September 1, 2007;
30(9):
2362 - 2368.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Warnberg, E. Nova, L. A Moreno, J. Romeo, M. I Mesana, J. R Ruiz, F. B Ortega, M. Sjostrom, M. Bueno, A. Marcos, et al.
Inflammatory proteins are related to total and abdominal adiposity in a healthy adolescent population: the AVENA Study.
Am. J. Clinical Nutrition,
September 1, 2006;
84(3):
505 - 512.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. P. H. van Wijk, M. C. Cabezas, E. J. P. de Koning, T. J. Rabelink, R. van der Geest, and I. M. Hoepelman
In Vivo Evidence of Impaired Peripheral Fatty Acid Trapping in Patients with Human Immunodeficiency Virus-Associated Lipodystrophy
J. Clin. Endocrinol. Metab.,
June 1, 2005;
90(6):
3575 - 3582.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. A. Tataranni and E. Ortega
A Burning Question: Does an Adipokine-Induced Activation of the Immune System Mediate the Effect of Overnutrition on Type 2 Diabetes?
Diabetes,
April 1, 2005;
54(4):
917 - 927.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Li, P. C. Pircher, I. G. Schulman, and S. K. Westin
Regulation of Complement C3 Expression by the Bile Acid Receptor FXR
J. Biol. Chem.,
March 4, 2005;
280(9):
7427 - 7434.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. Engstrom, B. Hedblad, K.-F. Eriksson, L. Janzon, and F. Lindgarde
Complement C3 Is a Risk Factor for the Development of Diabetes: A Population-Based Cohort Study
Diabetes,
February 1, 2005;
54(2):
570 - 575.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. M. Doherty, L. A. Fitzpatrick, D. Inoue, J.-H. Qiao, M. C. Fishbein, R. C. Detrano, P. K. Shah, and T. B. Rajavashisth
Molecular, Endocrine, and Genetic Mechanisms of Arterial Calcification
Endocr. Rev.,
August 1, 2004;
25(4):
629 - 672.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. J van Oostrom, H. van Dijk, C. Verseyden, A. D Sniderman, K. Cianflone, T. J Rabelink, and M. Castro Cabezas
Addition of glucose to an oral fat load reduces postprandial free fatty acids and prevents the postprandial increase in complement component 3
Am. J. Clinical Nutrition,
March 1, 2004;
79(3):
510 - 515.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. M. Fernandez-Real and W. Ricart
Insulin Resistance and Chronic Cardiovascular Inflammatory Syndrome
Endocr. Rev.,
June 1, 2003;
24(3):
278 - 301.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. M. Rogge
The Case for an Immunologic Cause of Obesity
Biol Res Nurs,
July 1, 2002;
4(1):
43 - 53.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Ozata, C. Oktenli, M. Gulec, T. Ozgurtas, F. Bulucu, K. Caglar, N. Bingol, A. Vural, and I. C. Ozdemir
Increased Fasting Plasma Acylation-Stimulating Protein Concentrations in Nephrotic Syndrome
J. Clin. Endocrinol. Metab.,
February 1, 2002;
87(2):
853 - 858.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. Vozarova, C. Weyer, R. S. Lindsay, R. E. Pratley, C. Bogardus, and P. A. Tataranni
High White Blood Cell Count Is Associated With a Worsening of Insulin Sensitivity and Predicts the Development of Type 2 Diabetes
Diabetes,
February 1, 2002;
51(2):
455 - 461.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Ozata, D. Gungor, M. Turan, G. Ozisik, N. Bingol, T. Ozgurtas, and I. C. Ozdemir
Improved Glycemic Control Increases Fasting Plasma Acylation-Stimulating Protein and Decreases Leptin Concentrations in Type II Diabetic Subjects
J. Clin. Endocrinol. Metab.,
August 1, 2001;
86(8):
3659 - 3664.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. A. Koistinen, H. Vidal, S.-L. Karonen, E. Dusserre, P. Vallier, V. A. Koivisto, and P. Ebeling
Plasma Acylation Stimulating Protein Concentration and Subcutaneous Adipose Tissue C3 mRNA Expression in Nondiabetic and Type 2 Diabetic Men
Arterioscler. Thromb. Vasc. Biol.,
June 1, 2001;
21(6):
1034 - 1039.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Weyer, T. Funahashi, S. Tanaka, K. Hotta, Y. Matsuzawa, R. E. Pratley, and P. A. Tataranni
Hypoadiponectinemia in Obesity and Type 2 Diabetes: Close Association with Insulin Resistance and Hyperinsulinemia
J. Clin. Endocrinol. Metab.,
May 1, 2001;
86(5):
1930 - 1935.
[Abstract]
[Full Text]
|
 |
|

|
 |

|
 |
 
K. Ylitalo, P. Pajukanta, S. Meri, R. M. Cantor, N. Mero-Matikainen, J. Vakkilainen, I. Nuotio, and M.-R. Taskinen
Serum C3 but Not Plasma Acylation-Stimulating Protein Is Elevated in Finnish Patients With Familial Combined Hyperlipidemia
Arterioscler. Thromb. Vasc. Biol.,
May 1, 2001;
21(5):
838 - 843.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2000 by the American Diabetes Association.
|
|
| |
|